Cargando…

Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy

IMPORTANCE: Central nervous system (CNS)–penetrant systemic therapies have significantly advanced care for patients with melanoma brain metastases. However, improved understanding of the molecular landscape and microenvironment of these lesions is needed to both optimize patient selection and advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasudevan, Harish N., Delley, Cyrille, Chen, William C., Mirchia, Kanish, Pan, Sixuan, Shukla, Poojan, Aabedi, Alex A., Nguyen, Minh P., Morshed, Ramin A., Young, Jacob S., Boreta, Lauren, Fogh, Shannon E., Nakamura, Jean L., Theodosopoulos, Philip V., Phillips, Joanna, Hervey-Jumper, Shawn L., Daras, Mariza, Pike, Luke, Aghi, Manish K., Tsai, Katy, Raleigh, David R., Braunstein, Steve E., Abate, Adam R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436135/
https://www.ncbi.nlm.nih.gov/pubmed/37589977
http://dx.doi.org/10.1001/jamanetworkopen.2023.29186
_version_ 1785092260199661568
author Vasudevan, Harish N.
Delley, Cyrille
Chen, William C.
Mirchia, Kanish
Pan, Sixuan
Shukla, Poojan
Aabedi, Alex A.
Nguyen, Minh P.
Morshed, Ramin A.
Young, Jacob S.
Boreta, Lauren
Fogh, Shannon E.
Nakamura, Jean L.
Theodosopoulos, Philip V.
Phillips, Joanna
Hervey-Jumper, Shawn L.
Daras, Mariza
Pike, Luke
Aghi, Manish K.
Tsai, Katy
Raleigh, David R.
Braunstein, Steve E.
Abate, Adam R.
author_facet Vasudevan, Harish N.
Delley, Cyrille
Chen, William C.
Mirchia, Kanish
Pan, Sixuan
Shukla, Poojan
Aabedi, Alex A.
Nguyen, Minh P.
Morshed, Ramin A.
Young, Jacob S.
Boreta, Lauren
Fogh, Shannon E.
Nakamura, Jean L.
Theodosopoulos, Philip V.
Phillips, Joanna
Hervey-Jumper, Shawn L.
Daras, Mariza
Pike, Luke
Aghi, Manish K.
Tsai, Katy
Raleigh, David R.
Braunstein, Steve E.
Abate, Adam R.
author_sort Vasudevan, Harish N.
collection PubMed
description IMPORTANCE: Central nervous system (CNS)–penetrant systemic therapies have significantly advanced care for patients with melanoma brain metastases. However, improved understanding of the molecular landscape and microenvironment of these lesions is needed to both optimize patient selection and advance treatment approaches. OBJECTIVE: To evaluate how bulk and single-cell genomic features of melanoma brain metastases are associated with clinical outcome and treatment response. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed bulk DNA sequencing and single nuclear RNA-sequencing data from resected melanoma brain metastases and included 94 consecutive patients with a histopathologically confirmed diagnosis of melanoma brain metastasis who underwent surgical resection at a single National Comprehensive Cancer Network cancer center in San Francisco, California, from January 1, 2009, to December 31, 2022. EXPOSURE: A Clinical Laboratory Improvement Amendments–certified targeted sequencing assay was used to analyze tumor resection specimens, with a focus on BRAF V600E alteration. For frozen pathologic specimens from CNS treatment-naive patients undergoing surgical resection, commercial single nuclear RNA sequencing approaches were used. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (OS). Secondary outcomes included CNS progression-free survival (PFS), microenvironmental composition with decreased T-cell and macrophage populations, and responses to immunotherapy. RESULTS: To correlate molecular status with clinical outcome, Kaplan-Meier survival analysis of 94 consecutive patients (median age, 64 years [range, 24-82 years]; 70 men [74%]) with targeted BRAF alteration testing showed worse median intracranial PFS (BRAF variant: 3.6 months [IQR, 0.1-30.6 months]; BRAF wildtype: 11.0 months [IQR, 0.8-81.5 months]; P < .001) and OS (BRAF variant: 9.8 months [IQR, 2.5-69.4 months]; BRAF wildtype: 23.2 months [IQR, 1.1-102.5 months]; P = .005; log-rank test) in BRAF V600E variant tumors. Multivariable Cox proportional hazards regression analysis revealed that BRAF V600E status was an independent variable significantly associated with both PFS (hazard ratio [HR], 2.65; 95% CI, 1.54-4.57; P < .001) and OS (HR, 1.96; 95% CI, 1.08-3.55; P = .03). For the 45 patients with resected melanoma brain metastases undergoing targeted DNA sequencing, molecular classification recapitulated The Cancer Genome Atlas groups (NRAS variant, BRAF variant, NF1 variant, and triple wildtype) with no subtype enrichment within the brain metastasis cohort. On a molecular level, BRAF V600E variant lesions were found to have a significantly decreased tumor mutation burden. Moreover, single nuclear RNA sequencing of treatment-naive BRAF V600E variant (n = 3) brain metastases compared with BRAF wildtype (n = 3) brain metastases revealed increased immune cell populations in BRAF wildtype tumors (mean [SD], 11% [4.1%] vs 3% [1.6%] CD45-positive cells; P = .04). Survival analysis of postoperative immunotherapy responses by BRAF status revealed that BRAF wildtype lesions were associated with a response to checkpoint inhibition (median OS: with immunotherapy, undefined; without immunotherapy, 13.0 months [range, 1.1-61.7 months]; P = .001; log-rank test) while BRAF variant lesions (median OS: with immunotherapy, 9.8 months [range, 2.9-39.8 months]; without immunotherapy, 9.5 months [range, 2.5-67.2 months]; P = .81; log-rank test) were not. CONCLUSIONS AND RELEVANCE: This molecular analysis of patients with resected melanoma brain metastases found that BRAF V600E alteration is an important translational biomarker associated with worse clinical outcomes, differential microenvironmental composition, and benefit from immunotherapy. Patients with BRAF V600E variant melanoma brain metastases may thus benefit from alternative CNS-penetrant systemic regimens.
format Online
Article
Text
id pubmed-10436135
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-104361352023-08-19 Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy Vasudevan, Harish N. Delley, Cyrille Chen, William C. Mirchia, Kanish Pan, Sixuan Shukla, Poojan Aabedi, Alex A. Nguyen, Minh P. Morshed, Ramin A. Young, Jacob S. Boreta, Lauren Fogh, Shannon E. Nakamura, Jean L. Theodosopoulos, Philip V. Phillips, Joanna Hervey-Jumper, Shawn L. Daras, Mariza Pike, Luke Aghi, Manish K. Tsai, Katy Raleigh, David R. Braunstein, Steve E. Abate, Adam R. JAMA Netw Open Original Investigation IMPORTANCE: Central nervous system (CNS)–penetrant systemic therapies have significantly advanced care for patients with melanoma brain metastases. However, improved understanding of the molecular landscape and microenvironment of these lesions is needed to both optimize patient selection and advance treatment approaches. OBJECTIVE: To evaluate how bulk and single-cell genomic features of melanoma brain metastases are associated with clinical outcome and treatment response. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed bulk DNA sequencing and single nuclear RNA-sequencing data from resected melanoma brain metastases and included 94 consecutive patients with a histopathologically confirmed diagnosis of melanoma brain metastasis who underwent surgical resection at a single National Comprehensive Cancer Network cancer center in San Francisco, California, from January 1, 2009, to December 31, 2022. EXPOSURE: A Clinical Laboratory Improvement Amendments–certified targeted sequencing assay was used to analyze tumor resection specimens, with a focus on BRAF V600E alteration. For frozen pathologic specimens from CNS treatment-naive patients undergoing surgical resection, commercial single nuclear RNA sequencing approaches were used. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (OS). Secondary outcomes included CNS progression-free survival (PFS), microenvironmental composition with decreased T-cell and macrophage populations, and responses to immunotherapy. RESULTS: To correlate molecular status with clinical outcome, Kaplan-Meier survival analysis of 94 consecutive patients (median age, 64 years [range, 24-82 years]; 70 men [74%]) with targeted BRAF alteration testing showed worse median intracranial PFS (BRAF variant: 3.6 months [IQR, 0.1-30.6 months]; BRAF wildtype: 11.0 months [IQR, 0.8-81.5 months]; P < .001) and OS (BRAF variant: 9.8 months [IQR, 2.5-69.4 months]; BRAF wildtype: 23.2 months [IQR, 1.1-102.5 months]; P = .005; log-rank test) in BRAF V600E variant tumors. Multivariable Cox proportional hazards regression analysis revealed that BRAF V600E status was an independent variable significantly associated with both PFS (hazard ratio [HR], 2.65; 95% CI, 1.54-4.57; P < .001) and OS (HR, 1.96; 95% CI, 1.08-3.55; P = .03). For the 45 patients with resected melanoma brain metastases undergoing targeted DNA sequencing, molecular classification recapitulated The Cancer Genome Atlas groups (NRAS variant, BRAF variant, NF1 variant, and triple wildtype) with no subtype enrichment within the brain metastasis cohort. On a molecular level, BRAF V600E variant lesions were found to have a significantly decreased tumor mutation burden. Moreover, single nuclear RNA sequencing of treatment-naive BRAF V600E variant (n = 3) brain metastases compared with BRAF wildtype (n = 3) brain metastases revealed increased immune cell populations in BRAF wildtype tumors (mean [SD], 11% [4.1%] vs 3% [1.6%] CD45-positive cells; P = .04). Survival analysis of postoperative immunotherapy responses by BRAF status revealed that BRAF wildtype lesions were associated with a response to checkpoint inhibition (median OS: with immunotherapy, undefined; without immunotherapy, 13.0 months [range, 1.1-61.7 months]; P = .001; log-rank test) while BRAF variant lesions (median OS: with immunotherapy, 9.8 months [range, 2.9-39.8 months]; without immunotherapy, 9.5 months [range, 2.5-67.2 months]; P = .81; log-rank test) were not. CONCLUSIONS AND RELEVANCE: This molecular analysis of patients with resected melanoma brain metastases found that BRAF V600E alteration is an important translational biomarker associated with worse clinical outcomes, differential microenvironmental composition, and benefit from immunotherapy. Patients with BRAF V600E variant melanoma brain metastases may thus benefit from alternative CNS-penetrant systemic regimens. American Medical Association 2023-08-17 /pmc/articles/PMC10436135/ /pubmed/37589977 http://dx.doi.org/10.1001/jamanetworkopen.2023.29186 Text en Copyright 2023 Vasudevan HN et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Vasudevan, Harish N.
Delley, Cyrille
Chen, William C.
Mirchia, Kanish
Pan, Sixuan
Shukla, Poojan
Aabedi, Alex A.
Nguyen, Minh P.
Morshed, Ramin A.
Young, Jacob S.
Boreta, Lauren
Fogh, Shannon E.
Nakamura, Jean L.
Theodosopoulos, Philip V.
Phillips, Joanna
Hervey-Jumper, Shawn L.
Daras, Mariza
Pike, Luke
Aghi, Manish K.
Tsai, Katy
Raleigh, David R.
Braunstein, Steve E.
Abate, Adam R.
Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy
title Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy
title_full Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy
title_fullStr Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy
title_full_unstemmed Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy
title_short Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy
title_sort molecular features of resected melanoma brain metastases, clinical outcomes, and responses to immunotherapy
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436135/
https://www.ncbi.nlm.nih.gov/pubmed/37589977
http://dx.doi.org/10.1001/jamanetworkopen.2023.29186
work_keys_str_mv AT vasudevanharishn molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT delleycyrille molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT chenwilliamc molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT mirchiakanish molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT pansixuan molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT shuklapoojan molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT aabedialexa molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT nguyenminhp molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT morshedramina molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT youngjacobs molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT boretalauren molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT foghshannone molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT nakamurajeanl molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT theodosopoulosphilipv molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT phillipsjoanna molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT herveyjumpershawnl molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT darasmariza molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT pikeluke molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT aghimanishk molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT tsaikaty molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT raleighdavidr molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT braunsteinstevee molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy
AT abateadamr molecularfeaturesofresectedmelanomabrainmetastasesclinicaloutcomesandresponsestoimmunotherapy